219 related articles for article (PubMed ID: 10993933)
21. Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates.
Heile JM; Fong YL; Rosa D; Berger K; Saletti G; Campagnoli S; Bensi G; Capo S; Coates S; Crawford K; Dong C; Wininger M; Baker G; Cousens L; Chien D; Ng P; Archangel P; Grandi G; Houghton M; Abrignani S
J Virol; 2000 Aug; 74(15):6885-92. PubMed ID: 10888628
[TBL] [Abstract][Full Text] [Related]
22. Heterogeneity of the humoral anti-HCV/E2 response in persistently infected patients as demonstrated by divergent patterns of inhibition of the binding of anti-HCV/E2 human monoclonal antibodies.
Mancini N; Canducci F; Carletti S; Berardinelli E; Serafini G; Grieco A; Perotti M; Malcangi G; Danieli MG; Varaldo PE; Clementi M; Burioni R
J Biol Regul Homeost Agents; 2003; 17(2):183-7. PubMed ID: 14518720
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein.
Machida K; Kondo Y; Huang JY; Chen YC; Cheng KT; Keck Z; Foung S; Dubuisson J; Sung VM; Lai MM
J Virol; 2008 Jul; 82(13):6711-20. PubMed ID: 18417597
[TBL] [Abstract][Full Text] [Related]
24. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes.
Gu J; Hardy J; Boo I; Vietheer P; McCaffrey K; Alhammad Y; Chopra A; Gaudieri S; Poumbourios P; Coulibaly F; Drummer HE
J Virol; 2018 May; 92(9):. PubMed ID: 29467319
[TBL] [Abstract][Full Text] [Related]
25. Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step.
Sabo MC; Luca VC; Prentoe J; Hopcraft SE; Blight KJ; Yi M; Lemon SM; Ball JK; Bukh J; Evans MJ; Fremont DH; Diamond MS
J Virol; 2011 Jul; 85(14):7005-19. PubMed ID: 21543495
[TBL] [Abstract][Full Text] [Related]
26. Longitudinal Sequence and Functional Evolution within Glycoprotein E2 in Hepatitis C Virus Genotype 3a Infection.
Alhammad YM; Maharajh S; Butcher R; Eden JS; White PA; Poumbourios P; Drummer HE
PLoS One; 2015; 10(5):e0126397. PubMed ID: 25970466
[TBL] [Abstract][Full Text] [Related]
27. Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants.
Khera T; Behrendt P; Bankwitz D; Brown RJP; Todt D; Doepke M; Khan AG; Schulze K; Law J; Logan M; Hockman D; Wong JAJ; Dold L; Gonzalez-Motos V; Spengler U; Viejo-Borbolla A; Ströh LJ; Krey T; Tarr AW; Steinmann E; Manns MP; Klein F; Guzman CA; Marcotrigiano J; Houghton M; Pietschmann T
J Hepatol; 2019 Apr; 70(4):593-602. PubMed ID: 30439392
[TBL] [Abstract][Full Text] [Related]
28. Mapping of a conformational epitope shared between E1 and E2 on the serum-derived human hepatitis C virus envelope.
Petit MA; Jolivet-Reynaud C; Peronnet E; Michal Y; Trépo C
J Biol Chem; 2003 Nov; 278(45):44385-92. PubMed ID: 12882983
[TBL] [Abstract][Full Text] [Related]
29. Identification of a domain containing B-cell epitopes in hepatitis C virus E2 glycoprotein by using mouse monoclonal antibodies.
Lee JW; Kim Km; Jung SH; Lee KJ; Choi EC; Sung YC; Kang CY
J Virol; 1999 Jan; 73(1):11-8. PubMed ID: 9847301
[TBL] [Abstract][Full Text] [Related]
30. Human antibodies from phage display libraries: expression of recombinant full length immunoglobulin G specific to the hepatitis C virus E2 glycoprotein.
Bugli F; Graffeo R; Pescatori M; Paroni Sterbini F; Torelli R; Masucci L; Manzara S; Fadda G
New Microbiol; 2009 Oct; 32(4):341-9. PubMed ID: 20128440
[TBL] [Abstract][Full Text] [Related]
31. Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein.
Flint M; Dubuisson J; Maidens C; Harrop R; Guile GR; Borrow P; McKeating JA
J Virol; 2000 Jan; 74(2):702-9. PubMed ID: 10623732
[TBL] [Abstract][Full Text] [Related]
32. Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies.
Keck ZY; Li TK; Xia J; Gal-Tanamy M; Olson O; Li SH; Patel AH; Ball JK; Lemon SM; Foung SK
J Virol; 2008 Jun; 82(12):6061-6. PubMed ID: 18400849
[TBL] [Abstract][Full Text] [Related]
33. Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection.
Meola A; Sbardellati A; Bruni Ercole B; Cerretani M; Pezzanera M; Ceccacci A; Vitelli A; Levy S; Nicosia A; Traboni C; McKeating J; Scarselli E
J Virol; 2000 Jul; 74(13):5933-8. PubMed ID: 10846074
[TBL] [Abstract][Full Text] [Related]
34. Junctional and somatic hypermutation-induced CX
Yi C; Xia J; He L; Ling Z; Wang X; Yan Y; Wang J; Zhao X; Fan W; Sun X; Zhang R; Ye S; Zhang R; Xu Y; Ma L; Zhang Y; Zhou H; Huang Z; Niu J; Long G; Lu J; Zhong J; Sun B
Cell Mol Immunol; 2021 Mar; 18(3):675-685. PubMed ID: 32235917
[TBL] [Abstract][Full Text] [Related]
35. Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2.
Owsianka A; Clayton RF; Loomis-Price LD; McKeating JA; Patel AH
J Gen Virol; 2001 Aug; 82(Pt 8):1877-1883. PubMed ID: 11457993
[TBL] [Abstract][Full Text] [Related]
36. Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection.
Deng K; Liu R; Rao H; Jiang D; Wang J; Xie X; Wei L
PLoS One; 2015; 10(9):e0138756. PubMed ID: 26406225
[TBL] [Abstract][Full Text] [Related]
37. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells.
Rosa D; Campagnoli S; Moretto C; Guenzi E; Cousens L; Chin M; Dong C; Weiner AJ; Lau JY; Choo QL; Chien D; Pileri P; Houghton M; Abrignani S
Proc Natl Acad Sci U S A; 1996 Mar; 93(5):1759-63. PubMed ID: 8700831
[TBL] [Abstract][Full Text] [Related]
38. Neutralization activity and kinetics of two broad-range human monoclonal IgG1 derived from recombinant Fab fragments and directed against Hepatitis C virus E2 glycoprotein.
Diotti RA; Sautto GA; Solforosi L; Mancini N; Clementi M; Burioni R
New Microbiol; 2012 Oct; 35(4):475-9. PubMed ID: 23109015
[TBL] [Abstract][Full Text] [Related]
39. Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2.
Roccasecca R; Ansuini H; Vitelli A; Meola A; Scarselli E; Acali S; Pezzanera M; Ercole BB; McKeating J; Yagnik A; Lahm A; Tramontano A; Cortese R; Nicosia A
J Virol; 2003 Feb; 77(3):1856-67. PubMed ID: 12525620
[TBL] [Abstract][Full Text] [Related]
40. Interaction of hepatitis C virus envelope glycoprotein E2 with the large extracellular loop of tupaia CD81.
Tian ZF; Shen H; Fu XH; Chen YC; Blum HE; Baumert TF; Zhao XP
World J Gastroenterol; 2009 Jan; 15(2):240-4. PubMed ID: 19132776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
